WHAT HAPPENED -
During a conference last week, Ryan Danks, Director of Civil Enforcement at the US Department of Justice’s Antitrust Division (DOJ), suggested that merging parties—not the antitrust enforcement...more
The US Federal Trade Commission (FTC) voted July 21, 2021, to repeal a 1995 policy statement that eliminated prior approval and prior notice provisions from most merger settlements. In repealing this longstanding policy—and...more
The US Court of Appeals for the First Circuit held that pharmaceutical companies that wrongly list patents in FDA’s Orange Book must prove they acted in good faith to avoid antitrust liability. In re Lantus Direct Purchaser...more
3/6/2020
/ Antitrust Litigation ,
Antitrust Provisions ,
Antitrust Violations ,
Corporate Counsel ,
Food and Drug Administration (FDA) ,
Orange Book ,
Patents ,
Pharmaceutical Industry ,
Pharmaceutical Patents ,
Sanofi-Aventis ,
Sherman Act
WHAT HAPPENED:
• On September 4, 2019, the US Department of Justice’s Antitrust Division (DOJ) sued to block Novelis Inc.’s proposed $2.6 billion acquisition of Aleris Corporation.
• DOJ alleged that the transaction would...more
10/14/2019
/ ABS ,
Acquisitions ,
Antitrust Division ,
Antitrust Investigations ,
Arbitration ,
Arbitrators ,
Corporate Counsel ,
Department of Justice (DOJ) ,
Divestiture ,
Federal Trade Commission (FTC) ,
Mergers